platelet aggregation testing were used. Although adenosine diphosphate-induced optical aggregation has been considered the gold standard for assessing clopidogrel effectiveness, it is time consuming and technically difficult. Point-of-care tests, such as the VerifyNow P2Y12 platelet function test (Accumetrics, Inc., San Diego, California), are being used more frequently both clinically and in research studies. Ex vivo measures of platelet aggregation are another means to tailor clopidogrel therapy for an individual patient. It is unclear which of these tests best predicts clopidogrel responsiveness.
It is likely that truly "personalized" clopidogrel therapy will require some combination of both genetic and ex vivo platelet aggregation testing. Although preliminary results for both of these modalities are promising, their role in practice still remains unclear.
Just as we are beginning to understand the role of individual patient variability in clopidogrel response, physicians will also soon be confronted with the question of which thienopyridine to use. Prasugrel data were presented to the Food and Drug Administration in September 2008, and although the need for further review of the data resulted in no action being taken, there might be a choice of agent in the near future. Prasugrel is metabolized in a more direct path, has a quicker onset of action, and is more potent than the current clopidogrel dosing. How will interventionalists use this agent, which might also have a greater bleeding risk? Some physicians in Europe are using the more potent agent acutely and shifting to clopidogrel for long-term administration. The data to drive the decisions are largely lacking except for concern for bleeding risk in patients who have had a prior cerebrovascular accident, are elderly, or are of small body size.
Cangrelor, an injectable thienopyridine with reversible platelet binding, is a very short half-life agent that might provide opportunities for very prompt antiplatelet activity and be useful as a bridge in patients who need to interrupt their therapy, because its effect will dissipate within a very short time.
Further investigation into many of the unresolved issues regarding protection of our patients from thrombosis after stent placement will undoubtedly be forthcoming. At the current time physicians caring for these patients have many questions, and guidelines are incomplete in their recommendations. Hopefully new evidence will be forthcoming in the near future to inform those guidelines so that patient care can be optimized. We look forward to publishing many of those pivotal investigations in this journal. 
